Strowd R, Ellingson B, Raymond C, Yao J, et al. Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma. J Neurooncol 2023 Oct 21. doi: 10.1007/s11060-023-04456.
PMID: 37864646